• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes.

作者信息

Packer Milton

机构信息

Baylor Heart and Vascular Institute, Baylor University Medical Center, Dallas, TX

出版信息

Diabetes Care. 2018 Jan;41(1):11-13. doi: 10.2337/dci17-0052.

DOI:10.2337/dci17-0052
PMID:29263193
Abstract
摘要

相似文献

1
Heart Failure: The Most Important, Preventable, and Treatable Cardiovascular Complication of Type 2 Diabetes.心力衰竭：2型糖尿病最重要、可预防且可治疗的心血管并发症
Diabetes Care. 2018 Jan;41(1):11-13. doi: 10.2337/dci17-0052.
2
Heart failure: A preventable and treatable complication of type 2 diabetes.心力衰竭：2型糖尿病可预防和可治疗的并发症。
J Diabetes. 2019 Jul;11(7):613-616. doi: 10.1111/1753-0407.12930. Epub 2019 Apr 29.
3
Heart failure, saxagliptin, and diabetes mellitus: observations from the SAVOR-TIMI 53 randomized trial.心力衰竭、沙格列汀和糖尿病：来自 SAVOR-TIMI 53 随机试验的观察结果。
Circulation. 2014 Oct 28;130(18):1579-88. doi: 10.1161/CIRCULATIONAHA.114.010389. Epub 2014 Sep 4.
4
Clinical and Echocardiographic Characteristics and Cardiovascular Outcomes According to Diabetes Status in Patients With Heart Failure and Preserved Ejection Fraction: A Report From the I-Preserve Trial (Irbesartan in Heart Failure With Preserved Ejection Fraction).根据心力衰竭和射血分数保留患者的糖尿病状态的临床和超声心动图特征和心血管结局：来自 I-Preserve 试验（伊贝沙坦治疗射血分数保留心力衰竭）的报告。
Circulation. 2017 Feb 21;135(8):724-735. doi: 10.1161/CIRCULATIONAHA.116.024593. Epub 2017 Jan 4.
5
Impact of Diabetes Mellitus on Hospitalization for Heart Failure, Cardiovascular Events, and Death: Outcomes at 4 Years From the Reduction of Atherothrombosis for Continued Health (REACH) Registry.糖尿病对心力衰竭、心血管事件和死亡住院的影响：来自持续健康降低动脉粥样硬化血栓形成（REACH）登记研究的 4 年结果。
Circulation. 2015 Sep 8;132(10):923-31. doi: 10.1161/CIRCULATIONAHA.114.014796. Epub 2015 Jul 7.
6
The association between BMI and hospitalization for heart failure in 83,021 persons with Type 2 diabetes: a population-based study from the Swedish National Diabetes Registry.BMI 与 83021 例 2 型糖尿病患者心力衰竭住院治疗的相关性：来自瑞典国家糖尿病注册中心的一项基于人群的研究。
Diabet Med. 2014 May;31(5):586-94. doi: 10.1111/dme.12340. Epub 2013 Nov 15.
7
Do dipeptidyl peptidase IV (DPP-IV) inhibitors cause heart failure?二肽基肽酶IV（DPP-IV）抑制剂会导致心力衰竭吗？
Clin Ther. 2014 Dec 1;36(12):2072-2079. doi: 10.1016/j.clinthera.2014.10.009. Epub 2014 Nov 13.
8
Assessment of the Risk of Hospitalization for Heart Failure With Dipeptidyl Peptidase-4 Inhibitors, Saxagliptin, Alogliptin, and Sitagliptin in Patients With Type 2 Diabetes, Using an Alternative Measure to the Hazard Ratio.使用除风险比之外的另一种指标评估2型糖尿病患者使用二肽基肽酶-4抑制剂（沙格列汀、阿格列汀和西他列汀）发生心力衰竭住院风险的情况。
Ann Pharmacother. 2017 Jul;51(7):570-576. doi: 10.1177/1060028017698496. Epub 2017 Mar 1.
9
Glucose-Lowering Therapies in Patients With Concomitant Diabetes Mellitus and Heart Failure: Finding the "Sweet Spot".合并糖尿病和心力衰竭患者的降糖治疗：寻找“甜蜜点”
JACC Heart Fail. 2018 Jan;6(1):27-29. doi: 10.1016/j.jchf.2017.09.002. Epub 2017 Oct 11.
10
Heart failure: SGLT2 inhibitors and heart failure -- clinical implications.心力衰竭：SGLT2 抑制剂与心力衰竭——临床意义。
Nat Rev Cardiol. 2016 Apr;13(4):185-6. doi: 10.1038/nrcardio.2016.35. Epub 2016 Mar 10.

引用本文的文献

1
Effectiveness of semaglutide on survival outcomes in patients with type 2 diabetes and chronic kidney disease.司美格鲁肽对2型糖尿病合并慢性肾脏病患者生存结局的有效性
Open Heart. 2025 Jul 8;12(2):e003382. doi: 10.1136/openhrt-2025-003382.
2
Comparative cardiovascular outcomes of semaglutide to dulaglutide in patients with type 2 diabetes.司美格鲁肽与度拉糖肽在2型糖尿病患者中的心血管结局比较
Sci Rep. 2025 Jul 1;15(1):21333. doi: 10.1038/s41598-025-06245-w.
3
Modeling recurrent heart failure risk in type 2 diabetes: impact of flexible HbA1c trajectories using nonhomogeneous Poisson processes.
2型糖尿病复发性心力衰竭风险建模：使用非齐次泊松过程的灵活糖化血红蛋白轨迹的影响
Front Endocrinol (Lausanne). 2025 Apr 21;16:1472846. doi: 10.3389/fendo.2025.1472846. eCollection 2025.
4
The Role of Resistin in Macrovascular and Microvascular Complications of Type 2 Diabetes.抵抗素在2型糖尿病大血管和微血管并发症中的作用
Life (Basel). 2025 Apr 2;15(4):585. doi: 10.3390/life15040585.
5
Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes.心力衰竭合并2型糖尿病患者中胰高血糖素样肽-1受体激动剂与二肽基肽酶4抑制剂的比较结局
J Am Heart Assoc. 2025 Feb 18;14(4):e037510. doi: 10.1161/JAHA.124.037510. Epub 2025 Feb 8.
6
Endogenous adenine is a potential driver of the cardiovascular-kidney-metabolic syndrome.内源性腺嘌呤是心血管-肾脏-代谢综合征的潜在驱动因素。
medRxiv. 2024 Aug 20:2024.08.19.24312277. doi: 10.1101/2024.08.19.24312277.
7
A self-reinforcing cycle hypothesis in heart failure pathogenesis.心力衰竭发病机制中的自我强化循环假说。
Nat Cardiovasc Res. 2024 Jun;3(6):627-636. doi: 10.1038/s44161-024-00480-6. Epub 2024 Jun 3.
8
Application of neutrophil-lymphocyte ratio and red blood cell distribution width in diabetes mellitus complicated with heart failure.中性粒细胞与淋巴细胞比值及红细胞分布宽度在糖尿病合并心力衰竭中的应用
World J Diabetes. 2024 Jun 15;15(6):1226-1233. doi: 10.4239/wjd.v15.i6.1226.
9
Glucagon-like peptide-1 receptor agonists and sodium-glucose cotransporter 2 inhibitors, anti-diabetic drugs in heart failure and cognitive impairment: potential mechanisms of the protective effects.胰高血糖素样肽-1受体激动剂和钠-葡萄糖协同转运蛋白2抑制剂，心力衰竭和认知障碍中的抗糖尿病药物：保护作用的潜在机制
Front Pharmacol. 2024 Jun 14;15:1422740. doi: 10.3389/fphar.2024.1422740. eCollection 2024.
10
The double burden: type 1 diabetes and heart failure-a comprehensive review.双重负担：1 型糖尿病与心力衰竭——全面综述。
Cardiovasc Diabetol. 2024 Feb 12;23(1):65. doi: 10.1186/s12933-024-02136-y.